|
Philippines Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Philippines Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for the Philippines .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Philippine pharmaceutical and healthcare industry.
Competitive intelligence, Philippine pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Philippine market.
The Philippines Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Philippines Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Philippine pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on the Philippines to test other views – a key input for successful budgeting and strategic business planning in the Philippine pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Philippine Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in the Philippines .
- Exploit The Latest Competitive Philippine Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in the Philippines .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Philippines Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Philippines Pharmaceutical And Healthcare Industry SWOT |
| Philippines Political SWOT |
| Philippines Economic SWOT |
| Philippines Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ranking |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
| The Philippines – Market Summary |
Chapter - Regulatory Regime |
| Table: History Of Bureau Of Food And Drugs (BFAD) |
| Recent Regulatory Developments |
| Intellectual Property Regime |
| IP Shortcomings |
| IP Disputes |
| Counterfeit Drugs |
| Pricing And Reimbursement Regime |
| Recent Pricing And Reimbursement Developments |
| Parallel Trade |
| International Co-operation |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Table: Top 10 Causes Of Mortality In The Philippines |
| Communicable Diseases |
| Healthcare Sector |
| Healthcare Sector Financing |
| Corruption |
| Medical Tourism |
| Pharmaceutical Industry |
| Table: Top 20 Leading Pharmaceutical Companies In The Philippines (PHPbn) |
| Table: Comparative Growth Trend Of Foreign & Local Companies In The Philippines 2003-2007 (PHPbn) |
| Table: Number Of Foreign & Local Companies Established From 2003 To 2007 |
| Domestic Industry |
| Foreign Companies |
| Biotechnology |
| Recent Biotechnology Developments |
| Traditional Medicines |
| Pharmaceutical Retail |
| Table: A Selection Of Members From The Drug Stores Association Of The Philippines (DSAP) |
| Table: Spread Of Drugstore Outlets In The Philippines As % Of Total, By Region |
| Recent Developments In Pharmaceutical Retail |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Philippines – Drug Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Industry |
| Table: Philippines – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic Chapter - |
| Q308 Acceleration Does Not Alter Downbeat View |
| Table: Philippines – Economic Activity |
| Prescription Market Forecast |
| Table: Top 10 Prescription Brands In The Philippines (MAT September 2007, PHPbn) |
| Table: Top 20 Therapeutic Categories In The Philippines (MAT September 2007, PHPbn) |
| Table: Philippines – Prescription Market Indicators, Historical Data and Forecasts (PHPmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Philippines – Patented Drugs Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Philippines – Generics Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| OTC Market Forecast |
| Table: Top 10 OTC Brands In The Philippines (MAT September 2007, PHPbn) |
| Table: Philippines – OTC Drugs Market Indicators, Historical Data and Forecasts (PHPmn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Philippines – Pharmaceuticals Trade Indicators, Historical Data And Forecasts (US$mn) |
| Medical Devices Forecasts |
| Table: Philippines Medical Device Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Philippines – Other Health Indicators, Historical Data And Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Leading Multinational Manufacturers |
| GlaxoSmithKline Philippines |
| Pfizer |
| Novartis |
| Merck & Co |
| Sanofi-Aventis |
| Abbott Laboratories |
| Bristol-Myers Squibb |
| Wyeth |
| Eli Lilly |
| AstraZeneca |
| Indigenous Manufacturers |
| Unilab |
| Pascual Laboratories |
| Pacific Pharma Generics |
| MediChem Pharmaceuticals |
Chapter - Country Snapshot: Philippines Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2007-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 2004-2006 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Philippines Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Philippines continued to be ranked as the 11th most attractive pharmaceutical market in the Asia Pacific region, according to BMI’s Business Environment Rankings for Q209. Nevertheless, BMI expects the country to somewhat improve this position over the next five-year period as the market matures, with more of the population being able to afford healthcare. Currently valued at PHP111.6bn (US$2.51bn), the size of the country’s pharmaceutical market is average in global terms, despite the country’s 85mn population. The recently approved Universally Accessible Cheaper and Quality Medicines Act of 2008 will result in lower prices but increased consumption, as those on the lowest incomes will be able to afford some pharmaceuticals for the first time.
Nevertheless, the expected year-on-year (y-o-y) growth over the next five years – at a compound annual growth rate (CAGR) of 8.2% in local currency terms – is also encouraging, given the current economic climate. By 2013, the market is expected to be worth PHP165.4bn (US$3.91bn), although the development of the patented drugs sector will continue to be discouraged by counterfeiting activities and certain shortcomings of the country’s regulatory and intellectual property (IP) environment. On the other hand, recent (as well as likely future) price reductions – part of the Universally Accessible Cheaper and Quality Medicines Act of 2008 – have the potential to hamper overall market development.
Nevertheless, the past few months have witnessed a number of activities by foreign drug makers. One of the most notable developments was the February 2009 announcement by new Chief Executive Officer (CEO) of Novartis Healthcare Philippines that the Philippines was among the 'next wave' of pharmaceutical markets in Asia and that the company is increasing its generics presence in the country. Simultaneously, the firm will leverage its higher margin patented drugs, supported by the high number of product approvals. Novartis Healthcare Philippines is also due to open its research centre in the capital city of Manila in June 2009, while also launching a discount card scheme for those with hypertension in March 2009.
In terms of the wider operating environment and in contrast to Thailand, for example, the economy of the Philippines, and by extension its healthcare sector, has the necessary fundamentals to resist the current global crisis. The country is translating this economic buoyancy into enlightened social schemes, such as the PHP100 (US$2.13) treatment pack project. Under the populist venture, patients on low incomes will be able to purchase 24 types of medicines at affordable prices, encompassing a full range of products from chronic disease therapeutics, such as antihypertensives, to acute interventions, such as antibiotics. This will be supported by the expected GDP expansion of 2.8% in 2009, driven by the business process outsourcing and agricultural sectors. Our forecast is worth highlighting given that – for many years – the country was seen as the 'sick man' of Asia due its slow economic growth. The Philippines currently spends 3.4% of GDP on health but we expect this figure to increase to 3.65% by 2013.
|
Philippines Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |